Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma.

Sandhu S, McNeil CM, LoRusso P, Patel MR, Kabbarah O, Li C, Sanabria S, Flanagan WM, Yeh RF, Brunstein F, Nazzal D, Hicks R, Lemahieu V, Meng R, Hamid O, Infante JR.

Invest New Drugs. 2019 Aug 5. doi: 10.1007/s10637-019-00832-1. [Epub ahead of print]

PMID:
31385109
2.

Modeling the Kinetics of Lipid-Nanoparticle- Mediated Delivery of Multiple siRNAs to Evaluate the Effect on Competition for Ago2.

Mihaila R, Ruhela D, Galinski B, Card A, Cancilla M, Shadel T, Kang J, Tep S, Wei J, Haas RM, Caldwell J, Flanagan WM, Kuklin N, Cherkaev E, Ason B.

Mol Ther Nucleic Acids. 2019 Jun 7;16:367-377. doi: 10.1016/j.omtn.2019.03.004. Epub 2019 Mar 23.

3.

The OncoSim model: development and use for better decision-making in Canadian cancer control.

Gauvreau CL, Fitzgerald NR, Memon S, Flanagan WM, Nadeau C, Asakawa K, Garner R, Miller AB, Evans WK, Popadiuk CM, Wolfson M, Coldman AJ.

Curr Oncol. 2017 Dec;24(6):401-406. doi: 10.3747/co.24.3850. Epub 2017 Dec 20.

4.

Development of a population-based microsimulation model of body mass index.

Hennessy D, Garner R, Flanagan WM, Wall R, Nadeau C.

Health Rep. 2017 Jun 21;28(6):20-30.

5.

Biennial lung cancer screening in Canada with smoking cessation-outcomes and cost-effectiveness.

Goffin JR, Flanagan WM, Miller AB, Fitzgerald NR, Memon S, Wolfson MC, Evans WK.

Lung Cancer. 2016 Nov;101:98-103. doi: 10.1016/j.lungcan.2016.09.013. Epub 2016 Sep 28.

PMID:
27794416
6.

Productivity costs of work loss associated with osteoarthritis in Canada from 2010 to 2031.

Sharif B, Garner R, Hennessy D, Sanmartin C, Flanagan WM, Marshall DA.

Osteoarthritis Cartilage. 2017 Feb;25(2):249-258. doi: 10.1016/j.joca.2016.09.011. Epub 2016 Sep 23.

7.

Implementing low-dose computed tomography screening for lung cancer in Canada: implications of alternative at-risk populations, screening frequency, and duration.

Evans WK, Flanagan WM, Miller AB, Goffin JR, Memon S, Fitzgerald N, Wolfson MC.

Curr Oncol. 2016 Jun;23(3):e179-87. doi: 10.3747/co.23.2988. Epub 2016 Jun 9.

8.

Using the Cancer Risk Management Model to evaluate the health and economic impacts of cytology compared with human papillomavirus DNA testing for primary cervical cancer screening in Canada.

Popadiuk C, Gauvreau CL, Bhavsar M, Nadeau C, Asakawa K, Flanagan WM, Wolfson MC, Coldman AJ, Memon S, Fitzgerald N, Lacombe J, Miller AB.

Curr Oncol. 2016 Feb;23(Suppl 1):S56-63. doi: 10.3747/co.23.2991. Epub 2016 Feb 29.

9.

Clarifying Assumptions and Outcomes in Cost-Effectiveness Analyses--Reply.

Goffin JR, Flanagan WM, Evans WK.

JAMA Oncol. 2016 Feb;2(2):278-9. doi: 10.1001/jamaoncol.2015.4462. No abstract available.

PMID:
26869003
10.

Risk of work loss due to illness or disability in patients with osteoarthritis: a population-based cohort study.

Sharif B, Garner R, Sanmartin C, Flanagan WM, Hennessy D, Marshall DA.

Rheumatology (Oxford). 2016 May;55(5):861-8. doi: 10.1093/rheumatology/kev428. Epub 2016 Jan 11.

PMID:
26759430
11.

Effects of Reductions in Body Mass Index on the Future Osteoarthritis Burden in Canada: A Population-Based Microsimulation Study.

Kopec JA, Sayre EC, Fines P, Flanagan WM, Nadeau C, Okhmatovskaia A, Wolfson MC; Simulation Technology for Applied Research Team.

Arthritis Care Res (Hoboken). 2016 Aug;68(8):1098-105. doi: 10.1002/acr.22796.

12.

The Population Health Model (POHEM): an overview of rationale, methods and applications.

Hennessy DA, Flanagan WM, Tanuseputro P, Bennett C, Tuna M, Kopec J, Wolfson MC, Manuel DG.

Popul Health Metr. 2015 Sep 3;13:24. doi: 10.1186/s12963-015-0057-x. eCollection 2015.

13.

Cost-effectiveness of Lung Cancer Screening in Canada.

Goffin JR, Flanagan WM, Miller AB, Fitzgerald NR, Memon S, Wolfson MC, Evans WK.

JAMA Oncol. 2015 Sep;1(6):807-13. doi: 10.1001/jamaoncol.2015.2472.

PMID:
26226181
14.

Projecting the direct cost burden of osteoarthritis in Canada using a microsimulation model.

Sharif B, Kopec J, Bansback N, Rahman MM, Flanagan WM, Wong H, Fines P, Anis A.

Osteoarthritis Cartilage. 2015 Oct;23(10):1654-63. doi: 10.1016/j.joca.2015.05.029. Epub 2015 Jun 5.

15.

Performance of the cancer risk management model lung cancer screening module.

Flanagan WM, Evans WK, Fitzgerald NR, Goffin JR, Miller AB, Wolfson MC.

Health Rep. 2015 May;26(5):11-8.

16.

Eligibility for low-dose computerized tomography screening among asbestos-exposed individuals.

Fitzgerald NR, Flanagan WM, Evans WK, Miller AB; Canadian Partnership against Cancer (CPAC) Cancer Risk Management (CRM) Lung Cancer Working.

Scand J Work Environ Health. 2015 Jul;41(4):407-12. doi: 10.5271/sjweh.3496. Epub 2015 Apr 3.

17.

High-throughput chemical modification of oligonucleotides for systematic structure-activity relationship evaluation.

Zewge D, Gosselin F, Kenski DM, Li J, Jadhav V, Yuan Y, Nerurkar SS, Tellers DM, Flanagan WM, Davies IW.

Bioconjug Chem. 2014 Dec 17;25(12):2222-32. doi: 10.1021/bc500453q. Epub 2014 Nov 21.

PMID:
25398098
18.

Development of a population-based microsimulation mode of physical activity in Canada.

Nadeau C, Wong SL, Flanagan WM, Oderkirk J, Manuel D, Wall R, Tremblay MS.

Health Rep. 2013 Oct;24(10):11-9.

19.

Canadian Cancer Risk Management Model: evaluation of cancer control.

Evans WK, Wolfson MC, Flanagan WM, Shin J, Goffin J, Miller AB, Asakawa K, Earle C, Mittmann N, Fairclough L, Oderkirk J, Finès P, Gribble S, Hoch J, Hicks C, Omariba DW, Ng E.

Int J Technol Assess Health Care. 2013 Apr;29(2):131-9. doi: 10.1017/S0266462313000044. Epub 2013 Mar 20.

PMID:
23514623
20.

siRNA-optimized Modifications for Enhanced In Vivo Activity.

Kenski DM, Butora G, Willingham AT, Cooper AJ, Fu W, Qi N, Soriano F, Davies IW, Flanagan WM.

Mol Ther Nucleic Acids. 2012 Jan 24;1:e5. doi: 10.1038/mtna.2011.4.

21.

Single-stranded microRNA mimics.

Chorn G, Klein-McDowell M, Zhao L, Saunders MA, Flanagan WM, Willingham AT, Lim LP.

RNA. 2012 Oct;18(10):1796-804. doi: 10.1261/rna.031278.111. Epub 2012 Aug 21.

22.

Adenosine modification may be preferred for reducing siRNA immune stimulation.

Fucini RV, Haringsma HJ, Deng P, Flanagan WM, Willingham AT.

Nucleic Acid Ther. 2012 Jun;22(3):205-10. doi: 10.1089/nat.2011.0334. Epub 2012 Apr 20.

23.

In vivo activity and duration of short interfering RNAs containing a synthetic 5'-phosphate.

Kenski DM, Willingham AT, Haringsma HJ, Li JJ, Flanagan WM.

Nucleic Acid Ther. 2012 Apr;22(2):90-5. doi: 10.1089/nat.2011.0333. Epub 2012 Mar 8.

PMID:
22400991
24.

Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye.

Zhong M, Gadek TR, Bui M, Shen W, Burnier J, Barr KJ, Hanan EJ, Oslob JD, Yu CH, Zhu J, Arkin MR, Evanchik MJ, Flanagan WM, Hoch U, Hyde J, Prabhu S, Silverman JA, Wright J.

ACS Med Chem Lett. 2012 Jan 31;3(3):203-6. doi: 10.1021/ml2002482. eCollection 2012 Mar 8.

25.

Rescue of Mtp siRNA-induced hepatic steatosis by DGAT2 siRNA silencing.

Tep S, Mihaila R, Freeman A, Pickering V, Huynh F, Tadin-Strapps M, Stracks A, Hubbard B, Caldwell J, Flanagan WM, Kuklin NA, Ason B.

J Lipid Res. 2012 May;53(5):859-67. doi: 10.1194/jlr.M021063. Epub 2012 Feb 21. Erratum in: J Lipid Res. 2012 Nov;53(11):2484. Huyhn, Felicia [corrected to Huynh, Felicia].

26.

mRNA knockdown by single strand RNA is improved by chemical modifications.

Haringsma HJ, Li JJ, Soriano F, Kenski DM, Flanagan WM, Willingham AT.

Nucleic Acids Res. 2012 May;40(9):4125-36. doi: 10.1093/nar/gkr1301. Epub 2012 Jan 16.

27.

Nucleoside optimization for RNAi: a high-throughput platform.

Butora G, Kenski DM, Cooper AJ, Fu W, Qi N, Li JJ, Flanagan WM, Davies IW.

J Am Chem Soc. 2011 Oct 26;133(42):16766-9. doi: 10.1021/ja2068774. Epub 2011 Sep 30.

PMID:
21942264
28.

Nucleobase and ribose modifications control immunostimulation by a microRNA-122-mimetic RNA.

Peacock H, Fucini RV, Jayalath P, Ibarra-Soza JM, Haringsma HJ, Flanagan WM, Willingham A, Beal PA.

J Am Chem Soc. 2011 Jun 22;133(24):9200-3. doi: 10.1021/ja202492e. Epub 2011 Jun 1.

29.

RNA-induced silencing complex-bound small interfering RNA is a determinant of RNA interference-mediated gene silencing in mice.

Wei J, Jones J, Kang J, Card A, Krimm M, Hancock P, Pei Y, Ason B, Payson E, Dubinina N, Cancilla M, Stroh M, Burchard J, Sachs AB, Hochman JH, Flanagan WM, Kuklin NA.

Mol Pharmacol. 2011 Jun;79(6):953-63. doi: 10.1124/mol.110.070409. Epub 2011 Mar 22.

PMID:
21427169
30.

Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9.

Ason B, Tep S, Davis HR Jr, Xu Y, Tetzloff G, Galinski B, Soriano F, Dubinina N, Zhu L, Stefanni A, Wong KK, Tadin-Strapps M, Bartz SR, Hubbard B, Ranalletta M, Sachs AB, Flanagan WM, Strack A, Kuklin NA.

J Lipid Res. 2011 Apr;52(4):679-87. doi: 10.1194/jlr.M013664. Epub 2011 Jan 24.

31.

Structure-activity relationship (SAR) of the α-amino acid residue of potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonists.

Zhong M, Hanan EJ, Shen W, Bui M, Arkin MR, Barr KJ, Evanchik MJ, Hoch U, Hyde J, Martell JR, Oslob JD, Paulvannan K, Prabhu S, Silverman JA, Wright J, Yu CH, Zhu J, Flanagan WM.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):307-10. doi: 10.1016/j.bmcl.2010.11.014. Epub 2010 Nov 5.

PMID:
21109434
32.

Validation of population-based disease simulation models: a review of concepts and methods.

Kopec JA, Finès P, Manuel DG, Buckeridge DL, Flanagan WM, Oderkirk J, Abrahamowicz M, Harper S, Sharif B, Okhmatovskaia A, Sayre EC, Rahman MM, Wolfson MC.

BMC Public Health. 2010 Nov 18;10:710. doi: 10.1186/1471-2458-10-710. Review.

33.

Persistence of seed-based activity following segmentation of a microRNA guide strand.

Chorn G, Zhao L, Sachs AB, Flanagan WM, Lim LP.

RNA. 2010 Dec;16(12):2336-40. doi: 10.1261/rna.2296210. Epub 2010 Oct 22.

34.

Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists.

Zhong M, Shen W, Barr KJ, Arbitrario JP, Arkin MR, Bui M, Chen T, Cunningham BC, Evanchik MJ, Hanan EJ, Hoch U, Huen K, Hyde J, Kumer JL, Lac T, Lawrence CE, Martell JR, Oslob JD, Paulvannan K, Prabhu S, Silverman JA, Wright J, Yu CH, Zhu J, Flanagan WM.

Bioorg Med Chem Lett. 2010 Sep 1;20(17):5269-73. doi: 10.1016/j.bmcl.2010.06.145. Epub 2010 Jul 23.

PMID:
20655213
35.

Analysis of acyclic nucleoside modifications in siRNAs finds sensitivity at position 1 that is restored by 5'-terminal phosphorylation both in vitro and in vivo.

Kenski DM, Cooper AJ, Li JJ, Willingham AT, Haringsma HJ, Young TA, Kuklin NA, Jones JJ, Cancilla MT, McMasters DR, Mathur M, Sachs AB, Flanagan WM.

Nucleic Acids Res. 2010 Jan;38(2):660-71. doi: 10.1093/nar/gkp913. Epub 2009 Nov 16.

36.

Development of a population-based microsimulation model of osteoarthritis in Canada.

Kopec JA, Sayre EC, Flanagan WM, Fines P, Cibere J, Rahman MM, Bansback NJ, Anis AH, Jordan JM, Sobolev B, Aghajanian J, Kang W, Greidanus NV, Garbuz DS, Hawker GA, Badley EM.

Osteoarthritis Cartilage. 2010 Mar;18(3):303-11. doi: 10.1016/j.joca.2009.10.010. Epub 2009 Oct 23.

37.

SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo.

Arbitrario JP, Belmont BJ, Evanchik MJ, Flanagan WM, Fucini RV, Hansen SK, Harris SO, Hashash A, Hoch U, Hogan JN, Howlett AR, Jacobs JW, Lam JW, Ritchie SC, Romanowski MJ, Silverman JA, Stockett DE, Teague JN, Zimmerman KM, Taverna P.

Cancer Chemother Pharmacol. 2010 Mar;65(4):707-17. doi: 10.1007/s00280-009-1076-8. Epub 2009 Aug 1.

PMID:
19649632
38.

2-Aminobenzimidazoles as potent Aurora kinase inhibitors.

Zhong M, Bui M, Shen W, Baskaran S, Allen DA, Elling RA, Flanagan WM, Fung AD, Hanan EJ, Harris SO, Heumann SA, Hoch U, Ivy SN, Jacobs JW, Lam S, Lee H, McDowell RS, Oslob JD, Purkey HE, Romanowski MJ, Silverman JA, Tangonan BT, Taverna P, Yang W, Yoburn JC, Yu CH, Zimmerman KM, O'Brien T, Lew W.

Bioorg Med Chem Lett. 2009 Sep 1;19(17):5158-61. doi: 10.1016/j.bmcl.2009.07.016. Epub 2009 Jul 9.

PMID:
19646866
39.

Trends in risk factors for cardiovascular disease in Canada: temporal, socio-demographic and geographic factors.

Lee DS, Chiu M, Manuel DG, Tu K, Wang X, Austin PC, Mattern MY, Mitiku TF, Svenson LW, Putnam W, Flanagan WM, Tu JV; Canadian Cardiovascular Outcomes Research Team.

CMAJ. 2009 Aug 4;181(3-4):E55-66. doi: 10.1503/cmaj.081629. Epub 2009 Jul 20.

40.

The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model.

VanderPorten EC, Taverna P, Hogan JN, Ballinger MD, Flanagan WM, Fucini RV.

Mol Cancer Ther. 2009 Apr;8(4):930-9. doi: 10.1158/1535-7163.MCT-08-0754.

41.

Discovery of a potent and selective aurora kinase inhibitor.

Oslob JD, Romanowski MJ, Allen DA, Baskaran S, Bui M, Elling RA, Flanagan WM, Fung AD, Hanan EJ, Harris S, Heumann SA, Hoch U, Jacobs JW, Lam J, Lawrence CE, McDowell RS, Nannini MA, Shen W, Silverman JA, Sopko MM, Tangonan BT, Teague J, Yoburn JC, Yu CH, Zhong M, Zimmerman KM, O'Brien T, Lew W.

Bioorg Med Chem Lett. 2008 Sep 1;18(17):4880-4. doi: 10.1016/j.bmcl.2008.07.073. Epub 2008 Jul 24.

PMID:
18678489
42.

Trends in physician-diagnosed osteoarthritis incidence in an administrative database in British Columbia, Canada, 1996-1997 through 2003-2004.

Kopec JA, Rahman MM, Sayre EC, Cibere J, Flanagan WM, Aghajanian J, Anis AH, Jordan JM, Badley EM.

Arthritis Rheum. 2008 Jul 15;59(7):929-34. doi: 10.1002/art.23827.

43.

Population health impact of cancer in Canada, 2001.

Boswell-Purdy J, Flanagan WM, Roberge H, Le Petit C, White KJ, Berthelot JM.

Chronic Dis Can. 2007;28(1-2):42-55.

44.

Small-molecule inhibition of TNF-alpha.

He MM, Smith AS, Oslob JD, Flanagan WM, Braisted AC, Whitty A, Cancilla MT, Wang J, Lugovskoy AA, Yoburn JC, Fung AD, Farrington G, Eldredge JK, Day ES, Cruz LA, Cachero TG, Miller SK, Friedman JE, Choong IC, Cunningham BC.

Science. 2005 Nov 11;310(5750):1022-5.

45.

Lifetime costs of colon and rectal cancer management in Canada.

Maroun J, Ng E, Berthelot JM, Le Petit C, Dahrouge S, Flanagan WM, Walker H, Evans WK.

Chronic Dis Can. 2003 Fall;24(4):91-101.

PMID:
14733758
46.

Potential impact of population-based colorectal cancer screening in Canada.

Flanagan WM, Le Petit C, Berthelot JM, White KJ, Coombs BA, Jones-McLean E.

Chronic Dis Can. 2003 Fall;24(4):81-8.

PMID:
14733756
47.

In situ assembly of enzyme inhibitors using extended tethering.

Erlanson DA, Lam JW, Wiesmann C, Luong TN, Simmons RL, DeLano WL, Choong IC, Burdett MT, Flanagan WM, Lee D, Gordon EM, O'Brien T.

Nat Biotechnol. 2003 Mar;21(3):308-14. Epub 2003 Feb 3.

PMID:
12563278
48.

ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.

Lenferink AE, Busse D, Flanagan WM, Yakes FM, Arteaga CL.

Cancer Res. 2001 Sep 1;61(17):6583-91.

49.

Hypoxia inhibits G1/S transition through regulation of p27 expression.

Gardner LB, Li Q, Park MS, Flanagan WM, Semenza GL, Dang CV.

J Biol Chem. 2001 Mar 16;276(11):7919-26. Epub 2000 Dec 8.

50.

Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells.

Cariou S, Donovan JC, Flanagan WM, Milic A, Bhattacharya N, Slingerland JM.

Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):9042-6.

Supplemental Content

Loading ...
Support Center